MTVA
MetaVia Inc. Common StockRecent alerts on MTVA
All signals →
SEC filing
MTVA Presents DA-1726 Phase 1 Results, 9.1% Mean Body Weight Reduction at Day 54, Favorable Tolerability and Exploratory Liver Improvements
6d ago
Scanner
Large up move: 53.7% (3.4x normal daily movement)
11d ago
Scanner
Large up move: 69.4% (3.4x normal daily movement)
13d ago
SEC filing
MTVA to Present 3 Late-Breaking Obesity & MASH Data at ADA 2026 Sessions
15d ago
SEC filing
MTVA to Present DA-1726 GLP-1/Glucagon Dual Agonist Data at EASL Congress 2026
22d ago
SEC filing
MTVA Doses First Patient in 48‑64 mg DA‑1726 Phase 1 Obesity Study, 40‑Subject Trial, Dual GLP‑1/GCGR Agonist
53d ago
News
Billionaire Johnson’s VC Fund Is Said to Shelve Sale of 40 China Tech Firms
112d ago
News
Meta Stock Carries Slump In 2026. Here's What Wall Street Is Saying Ahead Of Q4 Results.
132d ago
News
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
136d ago
News
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
138d ago
News
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
148d ago
Get push alerts for MTVA
Add it to your watchlist in the app and receive every signal the moment it fires.
Download for iOS